BioSpace News Archive

Bio-Thera Solutions, Ltd. announced that dosing has begun in a Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala®, to US-sourced and EU-sourced reference product in normal healthy volunteers.

MedMira Inc. announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test, the fastest SARS-CoV-2 Antigen test available.

Caris Life Sciences®, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced that George W. Sledge, Jr., M.D. has joined the company as Executive Vice President and Chief Medical Officer.

Matchpoint Therapeutics, a biotechnology company founded to leverage the power of covalency for the discovery of precision small molecule medicines, launched with $100 million in financing.

BeiGene announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of BRUKINSA® for the treatment of adult patients with chronic lymphocytic leukemia.

Myovant Sciences, announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fiscal quarter, ended September 30, 2022.

Phanes Therapeutics, Inc. announced that it has received clearance from the US Food and Drug Administration to commence Phase I studies with PT217, its anti-Delta-like ligand 3 /anti-Cluster of differentiation 47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers.

NanoViricides, Inc., reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022 with the Securities and Exchange Commission on Thursday, October 13, 2022.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported operating results for the fiscal year and fourth quarter ended July 31, 2022 and provided a business update on recent corporate and operational developments.